Rigel Pharmaceuticals (RIGL) could be a solid addition to your portfolio given a notable revision in the company's earnings estimates. While the stock has been gaining lately, the trend might continue since its earnings outlook is still improving.The rising trend in estimate revisions, which is a result of growing analyst optimism on the earnings prospects of this drug developer, should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in earnings esti ...

Shares of Rigel Pharmaceuticals (RIGL) have gained 7% over the past four weeks to close the last trading session at $18.47, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $33.67 indicates a potential upside of 82.3%.The average comprises six short-term price targets ranging from a low of $20 to a high of $57, with a standard deviation of $17.36. While the lowest estimate indica ...

Rigel Pharmaceuticals (RIGL) came out with quarterly earnings of $0.63 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to loss of $0.50 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 350%. A quarter ago, it was expected that this drug developer would post earnings of $0.55 per share when it actually produced earnings of $0.80, delivering a surprise of 45.45%.Over the last four quarters, the c ...

Q1 2025 Financial Results Presentation May 6, 2025 1 Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1955 ("PSLRA") relating to, among other things, continued development and expansion of our business, projected financial performance including sales and revenue growth, potential results of our Phase 1b study of R289 in R/R lower-risk MDS, future Phase 2 studies of olutasidenib in recurrent glioma, potentia ...

Rigel Pharmaceuticals (RIGL) Q1 2025 Earnings Call May 06, 2025 04:30 PM ET Speaker0 Greetings, and welcome to Rigel Pharmaceuticals Financial Conference Call for the First Quarter twenty twenty As a reminder, this conference is being recorded. It is now my pleasure to introduce our first speaker, Ray Furey, Rigel's Executive Vice President, General Counsel and Corporate Secretary. Thank you, Mr. Furey. You may begin. Speaker1 Welcome to our first quarter twenty twenty five financial results and business up ...

Exhibit 99.1 Rigel Reports First Quarter 2025 Financial Results and Provides Business Update SOUTH SAN FRANCISCO, Calif., May 6, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today reported financial results for the first quarter ended March 31, 2025, including sales of TAVALISSE (fostamatinib disodium hexahydrate), GAVRETO (pralsetinib) and REZLIDHIA (olutasidenib), and recent business progress. · Net p ...

WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Commission File Number 0-29889 Rigel Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 94-3248524 (St ...

Contact for Investors & Media: Investors: Rigel Pharmaceuticals, Inc. 650.624.1232 [email protected] Media: David Rosen Argot Partners Phone: 646.461.6387 SOURCE Rigel Pharmaceuticals, Inc. SOUTH SAN FRANCISCO, Calif., April 29, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its first quarter 2025 financial results after market close on Tuesday, May 6, 2025. Rigel senior management will follow the announcement with a live conference call and webcast at 4: ...

文章核心观点 - Rigel Pharmaceuticals获Zacks评级上调至买入，反映盈利预期上升，有望推动股价上涨 [1][2] 评级系统优势 - Zacks评级系统基于公司盈利情况，对个人投资者判断股价走势有用，避免华尔街分析师主观因素影响 [2] - Zacks评级系统利用盈利预期修正，将股票分为五类，有良好外部审计记录，1988年以来Zacks排名第一股票年均回报达25% [5][6] 盈利预期与股价关系 - 公司未来盈利潜力变化与股价短期走势强相关，机构投资者根据盈利和预期计算股票公允价值并交易，影响股价 [3] - Rigel盈利预期上升和评级上调意味着业务改善，投资者认可将推动股价上涨 [4] Rigel盈利预期情况 - 该制药公司预计2025财年每股收益1.19美元，同比增长20.2% [7] - 过去三个月，Zacks对该公司的共识预期提高了12.4% [7] 评级结论 - Zacks评级系统对超4000只股票保持买卖评级比例均衡，仅前5%为强力买入，前20%为买入 [8] - Rigel升至Zacks排名第二，处于前20%，暗示短期内股价可能上涨 [9]

Scientist and trader of biotech stock. Focus on trading around events such as trial results and NDA/BLA approvals. Also covering companies in industries regulated by the FDA. Articles present my opinion on stocks, but don't constitute investment advice.Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not re ...